Glimepiride
- Generic Name
- Glimepiride
- Brand Names
- Duetact, Tandemact
- Drug Type
- Small Molecule
- Chemical Formula
- C24H34N4O5S
- CAS Number
- 93479-97-1
- Unique Ingredient Identifier
- 6KY687524K
- Background
First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in accordance with progressive β cell failure a...
- Indication
Glimepiride is indicated for the management of type 2 diabetes in adults as an adjunct to diet and exercise to improve glycemic control as monotherapy.
...
- Associated Conditions
- Type 2 Diabetes Mellitus
- Associated Therapies
- -
A Study to Test MK-0941 in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-0941-017)
- Conditions
- Interventions
- First Posted Date
- 2008-11-18
- Last Posted Date
- 2015-12-17
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 143
- Registration Number
- NCT00792935
Insulin Glargine Combination Therapies in Type II Diabetics
- Conditions
- Interventions
- First Posted Date
- 2008-11-02
- Last Posted Date
- 2009-09-28
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 375
- Registration Number
- NCT00783744
- Locations
- 🇬🇧
Sanofi-Aventis Administrative Office, Guildford, United Kingdom
🇦🇹Sanofi aventis administrative office, Vienna, Austria
🇫🇷Sanofi-aventis administrative office, Paris, France
Effect of Exenatide, Sitagliptin or Glimepiride on Functional ß -Cell Mass
- Conditions
- Interventions
- First Posted Date
- 2008-10-20
- Last Posted Date
- 2022-06-07
- Lead Sponsor
- University of Pennsylvania
- Target Recruit Count
- 47
- Registration Number
- NCT00775684
- Locations
- 🇺🇸
Pennsylvania Hospital, Philadelphia, Pennsylvania, United States
🇺🇸Clinical and Translational Research Center, Hospital of University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸Rodebaugh Diabetes Center, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
Efficacy of Pioglitazone and Glimepiride Combination Therapy in Treating Subjects With Type 2 Diabetes Mellitus.
- Conditions
- Interventions
- First Posted Date
- 2008-10-10
- Last Posted Date
- 2010-07-05
- Lead Sponsor
- Takeda
- Target Recruit Count
- 91
- Registration Number
- NCT00770952
How Improvement in Control of Diabetes Influences the Production of a Hormone Produced in the Gut Which Improves the Release and Action of Insulin.
- Conditions
- Interventions
- First Posted Date
- 2008-09-05
- Last Posted Date
- 2012-12-05
- Lead Sponsor
- The Royal Bournemouth Hospital
- Target Recruit Count
- 74
- Registration Number
- NCT00747383
- Locations
- 🇬🇧
Royal Bournemouth Hospital, Bournemouth, Dorset, United Kingdom
A Randomised, db, Placebo-controlled Study of BI 1356 for 18 Weeks Followed by a 34 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Type 2 Diabetic Patients for Whom Treatment With Metformin is Inappropriate
- Conditions
- Interventions
- First Posted Date
- 2008-08-22
- Last Posted Date
- 2014-06-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 227
- Registration Number
- NCT00740051
- Locations
- 🇺🇸
1218.50.10011 Boehringer Ingelheim Investigational Site, Peoria, Arizona, United States
🇺🇸1218.50.10002 Boehringer Ingelheim Investigational Site, Eugene, Oregon, United States
🇵🇭1218.50.63007 Boehringer Ingelheim Investigational Site, Pasay, Philippines
Anti-Inflammatory Effects of Pioglitazone
- Conditions
- Interventions
- First Posted Date
- 2008-07-25
- Last Posted Date
- 2012-09-27
- Lead Sponsor
- Kurume University
- Target Recruit Count
- 70
- Registration Number
- NCT00722631
- Locations
- 🇯🇵
Kurume University Hospital, Kurume city, Japan
Optimal Oral Hypoglycaemic Agents (OHA) for Combination With Insulin Glargine (Sulfonylurea vs. Metformin)
- Conditions
- Interventions
- First Posted Date
- 2008-07-02
- Last Posted Date
- 2011-01-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 99
- Registration Number
- NCT00708578
- Locations
- 🇰🇷
Sanofi-Aventis Administrative Office, Seoul, Korea, Republic of
Effect of Dipeptidyl Peptidase-IV Inhibitor and Sulfonylurea on Glucose Variability and Oxidative Stress
- First Posted Date
- 2008-06-17
- Last Posted Date
- 2009-10-29
- Lead Sponsor
- The Catholic University of Korea
- Target Recruit Count
- 36
- Registration Number
- NCT00699322
- Locations
- 🇰🇷
Kangnam St. Mary's hospital, Seoul, Korea, Republic of
Efficacy and Safety of Dapagliflozin in Combination With Glimepiride (a Sulphonylurea) in Type 2 Diabetes Patients
- Conditions
- Interventions
- First Posted Date
- 2008-05-20
- Last Posted Date
- 2013-10-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 597
- Registration Number
- NCT00680745
- Locations
- 🇺🇦
Research Site, Zaporozhye, Ukraine
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.